AI Article Synopsis
- - The study examines the risk of ventricular arrhythmias in patients on QT-prolonging medications like sotalol after cardioversion of atrial fibrillation to sinus rhythm, specifically focusing on changes in the corrected QT interval (QTc) over a 24-hour period.
- - Fifty patients were monitored using Holter recordings for 24 hours following cardioversion, with 27 on sotalol and 23 on metoprolol, revealing significant diurnal variation in heart rate and QTc, especially in those on sotalol.
- - Results showed that 22% of patients on sotalol experienced over 20% of their heartbeats with QTc exceeding 500 ms, indicating a higher risk for pro
Article Abstract
Background: The risk of ventricular arrhythmias in patients on QT prolonging drugs is indicated to be increased early after cardioversion (CV) of atrial fibrillation (AF) to sinus rhythm (SR). Sotalol, used to prevent AF relapse, prolongs cardiac repolarization and corrected QT interval (QTc). A pronounced QTc prolongation is an established marker of pro-arrhythmias. Our objective was to use novel technique to quantify and evaluate the diurnal variation of the QTc interval after elective CV to SR in patients on sotalol or metoprolol.
Methods: Fifty patients underwent twelve-lead Holter recording for 24 hr after elective CV for persistent AF. All patients had the highest tolerable stable dose of sotalol (n = 27) or metoprolol (n = 23). Measurements of QT and RR intervals were performed on all valid beats.
Results: A clear diurnal variation of both HR and QTc was seen in both groups, more pronounced in patients on sotalol, where a high percentage of heartbeats with QTc >500 ms was observed, especially at night. Six patients (22%) on sotalol but none on metoprolol had >20% of all heart beats within the 24-hour recording with QTc >500 ms.
Conclusion: Twenty-four-hour Holter recordings with QT-measurement immediately after CV demonstrated that one in five patients on sotalol had >20% of all heart beats with prolonged QTc >500 ms, especially during night-time. The QTc diurnal variation was retained in patients on β-blockade or a potent class III anti-arrhythmic drug with β-blocking properties.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293609 | PMC |
| http://dx.doi.org/10.1111/anec.12834 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Health Care Resource Utilization With Dronedarone Versus Sotalol Following Catheter Ablation in Adults With Atrial Fibrillation.
Clin Cardiol
January 2025
Department of Medicine, Creighton University School of Medicine and CHI Health, Omaha, Nebraska, USA.
Background: Clinical trials support dronedarone use for atrial fibrillation (AF) following catheter ablation (CA); however, comparative data on health care resource utilization (HCRU) with other antiarrhythmic drugs are lacking.
Methods: Retrospective analysis of Merative MarketScan databases (January 01, 2012-March 31, 2020) comparatively assessed HCRU in US adults with AF who received dronedarone or sotalol post-CA. Patients with ≥ 12-months' pre-CA data were followed from post-CA index treatment to disenrollment, death, or study end.
Population Pharmacokinetics and Pharmacodynamics of Sotalol Following Expedited Intravenous Loading in Patients With Atrial Arrhythmias.
CPT Pharmacometrics Syst Pharmacol
January 2025
Division of Clinical Pharmacology, Department of Pediatrics, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA.
Sotalol, a class III antiarrhythmic agent, is used to maintain sinus rhythm in patients with atrial fibrillation or atrial flutter (AFIB/AFL). Despite its efficacy, sotalol's use is limited by its potential to cause life-threatening ventricular arrhythmias due to QT interval prolongation. Traditionally, sotalol administration required hospitalization to monitor these risks.
View Article and Find Full Text PDFHome Sotalol Initiation for the Management of Atrial and Ventricular Arrhythmias Using Remote Electrocardiographic Monitoring.
JACC Clin Electrophysiol
November 2024
Section of Cardiac Electrophysiology, Department of Cardiology, OhioHealth Heart and Vascular Physicians, Riverside Methodist Hospital, Columbus, Ohio, USA.
Background: Sotalol is a class III antiarrhythmic drug used for the management of patients with atrial fibrillation to maintain sinus rhythm. Sotalol-induced QT interval prolongation can be proarrhythmic and is conventionally initiated in an inpatient setting where routine electrocardiographic (ECG) monitoring is available while sotalol reaches the steady state. The emergence of cellular-compatible home ECG devices, such as AliveCor's Kardia Mobile 6L, which offers 6-lead ECG, has made it possible to accurately measure QT intervals outside the hospital.
View Article and Find Full Text PDFArrhythmias in Patients With Heart Failure Prescribed Dofetilide or Sotalol.
JACC Adv
November 2024
Department of Pharmacy Practice, College of Pharmacy, Purdue University, West Lafayette and Indianapolis, Indiana, USA.
Background: Heart failure (HF) with reduced ejection fraction (HFrEF) is a risk factor for drug-induced arrhythmias. It is unknown whether HF with preserved ejection fraction (HFpEF) also increases the risk.
Objectives: The purpose of this study was to determine if the risk of ventricular tachycardia (VT) and sudden cardiac arrest (SCA) is increased in patients with HFpEF prescribed dofetilide or sotalol.
Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia.
N Engl J Med
November 2024
From the QEII Health Sciences Centre, Dalhousie University, Halifax, NS (J.L.S., R.P., A.A.), Western University, London, ON (A.S.L.T., L.J.G.), the Population Health Research Institute (J.S.H.) and Hamilton Health Sciences Centre (G.A.), Hamilton, ON, the University of Ottawa Heart Institute (G.M.N., P.B.N.), the McGill University Health Centre (V.E.), the Montreal Heart Institute (L.R., K.D.), and Centre Hospitalier de l'Universitaire de Montreal (J.-M.R.), Montreal, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC (J.-F.R.), Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec (J.-F.S., I.N.), the University of British Columbia, Vancouver (M.D.), Kelowna General Hospital, Kelowna, BC (C.L.), the University of Ottawa, Ottawa (G.A.W.), and the University of Calgary, Calgary, AB (V.K., S.W.) - all in Canada; Vanderbilt University Medical Center, Nashville (W.G.S., A.K.); Centre Hospitalier Universitaire de Bordeaux, L'institut des Maladies du Rythme Cardiaque, Bordeaux (F.S.), and Centre Hospitalier Universitaire de Nancy, Nancy (C.C.) - both in France; and St. Mary's General Hospital, Passaic, NJ (U.J.).
Background: Patients with ventricular tachycardia and ischemic cardiomyopathy are at high risk for adverse outcomes. Catheter ablation is commonly used when antiarrhythmic drugs do not suppress ventricular tachycardia. Whether catheter ablation is more effective than antiarrhythmic drugs as a first-line therapy in patients with ventricular tachycardia is uncertain.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!